Syndax Pharmaceuticals (SNDX)
Markets targeted therapies for acute leukemias and chronic graft-versus-host disease.
$17.29
vs last close−0.90 (−4.95%)
Something off on this page? Send us feedback.
Next report
Nov 2, 26
in 40 days
EPS estimate
−$0.51
Revenue estimate
$82.8M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Feb '26Apr '26Aug '26Nov '26
Reported−$1.10−$0.98−$0.83−$0.70−$0.78−$0.48−$0.55Pending
Estimate−$1.08−$1.04−$1.00−$0.74−$0.58−$0.59−$0.45−$0.51
Surprise−1.9%+5.8%+17.0%+5.4%−33.6%+18.6%−22.9%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Feb '26Apr '26Aug '26Nov '26
Reported$7.7M$20.0M$38.0M$45.9M$68.7M$64.9M$72.8MPending
Estimate$12.8M$18.5M$45.7M$63.3M$64.3M$69.8M$79.4M$82.8M
Surprise−39.9%+8.1%−16.9%−27.6%+6.9%−7.0%−8.3%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.14 | — | — |
| Sep 2027 | −$0.09 | — | — |
| Jun 2027 | −$0.18 | — | — |
| Mar 2027 | −$0.07 | — | — |
| Dec 2026 | −$0.44 | — | — |
| Nov 2026 | −$0.51 | — | — |
| Aug 2026 | −$0.45 | −$0.55 | −22.9% |
| Apr 2026 | −$0.59 | −$0.48 | +18.6% |
| Feb 2026 | −$0.58 | −$0.78 | −33.6% |
| Nov 2025 | −$0.74 | −$0.70 | +5.4% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Dec 2015 | |||
| Mar 2016 | |||
| Jun 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.14 | — | — | $64.9M | — | — | — |
| Sep 2027 | −$0.09 | — | — | $72.8M | — | — | — |
| Jun 2027 | −$0.18 | — | — | $72.8M | — | — | — |
| Mar 2027 | −$0.07 | — | — | $64.9M | — | — | — |
| Dec 2026 | −$0.44 | — | — | $97.0M | — | — | — |
| Nov 2, 2026 | −$0.51 | — | — | $82.8M | — | — | — |
| Aug 4, 2026 | −$0.45 | −$0.55 | −22.9% | $79.4M | $72.8M | −8.3% | +4.4% |
| Apr 30, 2026 | −$0.59 | −$0.48 | +18.6% | $69.8M | $64.9M | −7.0% | −10.8% |
| Feb 26, 2026 | −$0.58 | −$0.78 | −33.6% | $64.3M | $68.7M | +6.9% | +5.0% |
| Nov 3, 2025 | −$0.74 | −$0.70 | +5.4% | $63.3M | $45.9M | −27.6% | +11.6% |
| Aug 4, 2025 | |||||||
| May 5, 2025 | |||||||
| Mar 3, 2025 | |||||||
| Nov 5, 2024 | |||||||
| Aug 1, 2024 | |||||||
| May 8, 2024 | |||||||
| Feb 27, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 8, 2023 | |||||||
| Feb 28, 2023 | |||||||
| Nov 3, 2022 | |||||||
| Aug 8, 2022 | |||||||
| May 9, 2022 | |||||||
| Mar 1, 2022 | |||||||
| Nov 15, 2021 | |||||||
| Aug 9, 2021 | |||||||
| May 11, 2021 | |||||||
| Mar 8, 2021 | |||||||
| Nov 2, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 3, 2020 | |||||||
| Nov 7, 2019 | |||||||
| Aug 7, 2019 | |||||||
| May 6, 2019 | |||||||
| Mar 7, 2019 | |||||||
| Nov 5, 2018 | |||||||
| Aug 7, 2018 | |||||||
| May 8, 2018 | |||||||
| Mar 5, 2018 | |||||||
| Nov 7, 2017 | |||||||
| Aug 10, 2017 | |||||||
| May 8, 2017 | |||||||
| Mar 2, 2017 | |||||||
| Nov 10, 2016 | |||||||
| Aug 9, 2016 | |||||||
| May 16, 2016 | |||||||
| Dec 31, 2015 | |||||||
| Mar 3, 2016 | |||||||
| Jun 30, 2015 |